Evidence for association of coronary sinus levels of hepatocyte growth factor and collateralization in human coronary disease

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 284, Issue 5 53-5, 2003, Pages

  Lenihan, Daniel J ^a   Osman, Abdulfatah ^b   Sriram, Vissa ^b   Aitsebaomo, Julius ^c   Patterson, Cam ^c,d  

^a Cardiouascular Specialists of Texas   (United States)

^b University of Texas Medical Branch School of Medicine   (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Angiogenesis; Endothelial growth factors; Ischemia

Indexed keywords

SCATTER FACTOR; VASCULOTROPIN;

ADULT; AGED; AORTA; ARTICLE; CLINICAL ARTICLE; COLLATERAL CIRCULATION; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY SINUS; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; FEMALE; HEART CATHETERIZATION; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HUMAN; MALE; PRIORITY JOURNAL; PROTEIN CONTENT; PULMONARY ARTERY; RISK FACTOR; TISSUE LEVEL;

EID: 0037405791     PISSN: 03636135     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpheart.00429.2002     Document Type: Article

References (35)

1. Aoki M, Morishita R, Taniyama Y, Kida I, Moriguchi A, Matsumoto K, Nakamura T, Kaneda Y, Higaki J, and Ogihara T. Angiogenesis induced by hepatocyte growth factor in non-infarcted myocardium and infarcted myocardium: up-regulation of essential transcription factor for angiogenesis, etcs. Gene Ther 7: 417-427, 2000.
2. Banai S, Jaklitsch MT, Shou M, Lazarous DF, Scheinowitz M, Biro S, Epstein SE, and Unger EF. Angiogenic-induced enhancement of collateral blood flow to ischemic myocardium by vascular endothelial growth factor in dogs. Circulation 89: 2183-2189, 1994.
3. Banai S, Shweiki D, Pinson A, Chandra M, Lazarovici G, and Keshet E. Upregulation of vascular endothelial growth factor expression induced by myocardial ischaemia: implications for coronary angiogenesis. Cardiovasc Res 28: 1176-1179, 1994.
4. Celletti FL, Waugh JM, Amabile PG, Brendolan A, Hilfiker PR, and Dake MD. Vascular endothelial growth factor enhances atherosclerotic plaque progression. Nat Med 7: 425-429, 2001.
5. Charney R and Cohen M. The role of the coronary collateral circulation in limiting myocardial ischemia and infarct size. Am Heart J 126: 937-945, 1993.
6. Clements IP, Christian TF, Higano ST, Gibbons RJ, and Gersh BJ. Residual flow to the infarct zone as a determinant of infarct size after direct angioplasty. Circulation 88: 1527-1533, 1993.
7. Fleisch M, Billinger M, Eberli FR, Ali R, Garachemani AR, Meier B, and Seiler C. Physiologically assessed coronary collateral flow and intracoronary growth factor concentrations in patients with 1- to 3-vessel coronary artery disease. Circulation 100: 1945-1950, 1999.
8. Fujita M, Ikemoto M, Kishishita M, Otani H, Nohara R, Tanaka T, Tamaki S, Yamazato A, and Sasayama S. Elevated basic fibroblast growth factor in pericardial fluid of patients with unstable angina. Circulation 94: 610-613, 1996.
9. Giordano FJ, Ping P, McKirnan MD, Nozaki S, DeMaria AN, Dillmann WH, Mathieu-Costello O, and Hammond HK. Intracoronary gene transfer of fibroblast growth factor-5 increases blood flow and contractile function in an ischemic region of the heart. Nat Med 5: 534-539, 2000.
10. Hendel RC, Henry TD, Rocha-Singh K, Isner JM, Kereiakes DJ, Giordano FJ, Simons M, and Bonow RO. Effect of intracoronary recombinant human vascular endothelial growth factor on myocardial perfusion: evidence for a dose-dependent effect. Circulation 101: 118-121, 2000.
11. Hojo Y, Ikeda U, Zhu Y, Okada M, Ueno S, Arakawa H, Fujikawa H, Katsuki TA, and Shimada K. Expression of vascular endothelial growth factor in patients with acute myocardial infarction. J Am Coll Cardiol 35: 968-973, 2000.
12. Inoue M, Itoh H, Ueda M, Naruko T, Kojima A, Komatsu R, Doi K, Ogawa Y, Tamura N, Takaya K, Igaki T, Yamashita J, Chun TH, Masatsugu K, Becker AE, and Nakao K. Vascular endothelial growth factor (VEGF) expression in human coronary atherosclerotic lesions: possible pathophysiological significance of VEGF in progression of atherosclerosis. Circulation 98: 2108-2116, 1998.
13. Kranz A, Rau C, Kochs M, and Waltenberger J. Elevation of vascular endothelial growth factor-A serum levels following acute myocardial infarction. Evidence for its origin and functional significance. J Mol Cell Cardiol 32: 65-72, 2000.
14. Laham RJ, Chronos NA, Pike M, Leimbach ME, Udelson JE, Pearlman JD, Pettigrew RI, Whitehouse MJ, Yoshizawa C, and Simons M. Intracoronary basic fibroblast growth factor (FGF-2) in patients with severe ischemic heart disease: results of a phase I open-label dose escalation study. J Am Coll Cardiol 36: 2132-2139, 2000.
15. Lazarous DF, Shou M, Scheinowitz M, Hodge E, Thirumurti V, Kitsiou AN, Stiber JA, Lobo AD, Hunsberger S, Guetta E, Epstein SE, and Unger EF. Comparative effects of basic fibroblast growth factor and vascular endothelial growth factor on coronary collateral development and the arterial response to injury. Circulation 94: 1074-1082, 1996.
16. Lee CW, Park SW, Cho GY, Hong MK, Kim JJ, Kang DH, Song JK, Lee HJ, and Park SJ. Pressure-derived fractional collateral blood flow: a primary determinant of left ventricular recovery after reperfused acute myocardial infarction. J Am Coll Cardiol 35: 949-955, 2000.
17. Lee SH, Wolf PL, Escudero R, Deutsch R, Jamieson SW, and Thistlethwaite PA. Early expression of angiogenesis factors in acute myocardial ischemia and infarction. N Engl J Med 342: 626-633, 2000.
18. Morishita R, Nakamura S, Hayashi S, Taniyama Y, Moriguchi A, Nagano T, Taiji M, Noguchi H, Takeshita S, Matsumoto K, Nakamura T, Higaki J, and Ogihara T. Therapeutic angiogenesis induced by human recombinant hepatocyte growth factor in rabbit hind limb ischemia model as cytokine supplement therapy. Hypertension 33: 1379-1384, 1999.
19. Nakamura S, Moriguchi A, Morishita R, Aoki M, Yo Y, Hayashi S, Nakano N, Katsuya T, Nakata S, Takami S, Matsumoto K, Nakamura T, Higaki J, and Ogihara T. A novel vascular modulator, hepatocyte growth factor, as a potential index of the severity of hypertension. Biochem Biophys Res Commun 242: 238-243, 1998.
20. Nakamura S, Morishita R, Moriguchi A, Yo Y, Nakamura Y, Hayashi S, Matsumoto K, Matsumoto K, Nakamura T, Higaki J, and Ogihara T. Hepatocyte growth factor as a potential index of complication in diabetes mellitus. J Hypertens 16: 2019-2026, 1998.
21. Nakamura T, Mizuno S, Matsumoto K, Yoshiki S, Matsuda H, and Nakamura T. Myocardial protection from ischemia/reperfusion injury by endogenous and exogenous HGF. J Clin Invest 106: 1511-1519, 2000.
22. Ono K, Matsumori A, Shioi T, Yutaka F, and Sasayama S. Enhanced expression of hepatocyte growth factor/c-Met by myocardial ischemia and reperfusion in a rat model. Circulation 95: 2552-2558, 1997.
23. Rentrop KP, Cohen M, Blanke H, and Phillips RA. Changes in collateral channel filling immediately after controlled coronary artery occlusion by an angioplasty balloon in human subjects. J Am Coll Cardiol 5: 587-592, 1985.
24. Rosengart TK, Lee LY, Patel SR, Sanborn TA, Parikh M, Bergman GW, Hachamovitch R, Szulc M, Kligfield PD, Okin PM, Hahn RT, Devereaux RB, Post MR, Hackett NR, Foster T, Grasso TM, Lesser ML, Isom OW, and Crystal RG. Angiogenesis gene therapy: phase I assessment of direct intramyocardial administration of an adenovirus vector expressing VEGF121 cDNA to individuals with clinically significant severe coronary artery disease. Circulation 100: 468-474, 1999.
25. Ruef J, Hu ZY, Yin LY, Wu Y, Hanson SR, Kelly AB, Harker LA, Gadiparthi NR, Runge MS, and Patterson C. Induction of vascular endothelial growth factor in balloon-injured baboon arteries. A novel role for reactive oxygen species in atherosclerosis. Circ Res 81: 24-33, 1997.
26. Sabia PJ, Powers ER, Ragosta M, Sarembock IJ, Burwell LR, and Kaul S. An association between collateral blood flow and myocardial viability in patients with recent myocardial infarction. N Engl J Med 327: 1825-1831, 1992.
27. Schaper W and Kubin T. Is hepatocyte growth factor a protein with cardioprotective activity in the ischemic heart? Circulation 95: 2471-2472, 1997.
28. Schultz A, Lavie L, Hochberg I, Beyar R, Stone T, Skorecki K, Lavie P, Roguin A, and Levy AP. Interindividual heterogeneity in the hypoxic regulation of VEGF: significance for the development of the coronary artery collateral circulation. Circulation 100: 547-552, 1999.
29. Shweiki D, Itin A, Soffer D, and Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxiainitiated angiogenesis. Nature 359: 843-845, 1992.
30. Simons M. Therapeutic coronary angiogenesis: a fronte praecipitium a tergo lupi? Am J Physiol Heart Circ Physiol 280: H1923-H1927, 2001.
31. Soeki T, Tamura Y, Shinohara H, Tanaka H, Bando K, and Fukuda N. Serial changes in serum VEGF and HGF in patients with acute myocardial infarction. Cardiology 93: 168-174, 2000.
32. Udelson JE, Dilsizian V, Laham RJ, Chronos N, Vansant J, Blais M, Galt JR, Pike M, Yoshizawa C, and Simons M. Therapeutic angiogenesis with recombinant fibroblast growth factor-2 improves stress and rest myocardial perfusion abnormalities in patients with severe symptomatic chronic coronary artery disease. Circulation 102: 1605-1610, 2000.
33. Vale PR, Losordo DW, Milliken CE, Maysky M, Esakof DD, Symes JF, and Isner JM. Left ventricular electromechanical mapping to assess efficacy of phVEGF(165) gene transfer for therapeutic angiogenesis in chronic myocardial ischemia. Circulation 102: 965-974, 2000.
34. Yoshida N, Fujita M, Yamanishi K, and Miwa K. Relation between collateral channel filling and flow grade in recipient coronary arteries in patients with stable effort angina. J Am Coll Cardiol 22: 426-430, 1993.
35. Zhu Y, Hojo Y, Ikeda U, and Shimada K. Production of hepatocyte growth factor during acute myocardial infarction. Heart 83: 450-455, 2000.